1. Home
  2. BHF vs ACAD Comparison

BHF vs ACAD Comparison

Compare BHF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brighthouse Financial Inc.

BHF

Brighthouse Financial Inc.

HOLD

Current Price

$62.61

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.80

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHF
ACAD
Founded
2016
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
BHF
ACAD
Price
$62.61
$21.80
Analyst Decision
Hold
Buy
Analyst Count
8
22
Target Price
$57.71
$30.55
AVG Volume (30 Days)
405.5K
1.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
$27.10
$18.80
Revenue Next Year
$1.09
$11.70
P/E Ratio
$4.34
$9.80
Revenue Growth
N/A
40.45
52 Week Low
$43.16
$14.45
52 Week High
$66.33
$28.35

Technical Indicators

Market Signals
Indicator
BHF
ACAD
Relative Strength Index (RSI) 65.41 47.72
Support Level $59.04 $21.51
Resistance Level $62.63 $22.03
Average True Range (ATR) 0.54 0.61
MACD 0.06 0.04
Stochastic Oscillator 94.13 42.51

Price Performance

Historical Comparison
BHF
ACAD

About BHF Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: